Overspending Driven by Oversized Single Dose Vials of Cancer Drugs
Drug companies will make $1.8 billion this year by using package sizes that promote waste.
Even though reducing waste in healthcare is a top priority, analysts have missed the waste that can be created when expensive infused drugs are packaged containing quantities larger than the amount needed.
Peter B. Bach and colleagues call for an end to contradictory regulatory standards in the U.S. that allow drug manufacturers to boost profits by producing single dose vials containing quantities that increase leftover drug.
Read the analysis in the BMJ here.